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Abstract
This case highlights two common pre-analytical problems identified in routine coagulation testing of activated partial thromboplastin time (aPTT), 
which were overlooked because of a concurrent flag code indicating no coagulation and the result was replaced by asterisks. It concerns a boy with 
gastrointestinal bleeding and prolonged aPTT > 300 seconds, which raised the suspicion of haemophilia. When all other coagulation parameters 
(including specific coagulation factors VIII and IX) turned out to be normal, aPTT was re-measured using another analysis principle, which revealed 
a normal aPTT. The primary aPTT result turned out to be aborted due to concurrent haemolysis and lipaemia, but was erroneously interpreted as 
prolonged coagulation. The lesson is awareness of the possibility of numerous flag codes on the same sample overruling each other, and awareness 
on the responsibility in the post-analytical phase that must be carried by increased educational focus and by the manufacturers.
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A laboratory test result can be affected by interfer-
ing factors throughout the entire test process, 
which can be divided into the pre-analytical, ana-
lytical and post-analytical phase; all these phases 
must therefore be taken into account in order to 
interpret a test result correctly (1). A lot of effort is 
put into minimizing medical errors arising from 
laboratory diagnostics, especially errors emerging 
in relation to the pre-analytical phase as they con-
stitute the vast majority with a reported frequency 
of 70% of total errors in laboratory testing (2). 
Among these, endogenous interference is a fre-
quent reason for inappropriate quality of the spec-
imen. Also, the post-analytical phase related to re-
porting test results and interpretation of these can 
be source of errors in laboratory testing, although 
less data are available on this area.
Among pre-analytical errors, interference is fre-
quently observed from haemoglobin, bilirubin 
and lipaemia (HIL), the so-called HIL indices. Im-
portantly, the complexity of haemostasis and intri-
cacy of analytical methods makes coagulation 
testing more vulnerable to HIL interferences than 
other areas of in vitro laboratory diagnostics (1,3). 
Activated partial thromboplastin time (aPTT) esti-
mates the activity of the intrinsic and common 
pathways of coagulation by measuring the time in 
seconds required for a fibrin clot to form in a plas-
ma sample with appropriate amounts of calcium 
chloride and a thromboplastin reagent. The analy-
sis is mostly performed as a part of series of 
screening tests for bleeding tendency (4). In a rou-
tine setting, aPTT can be measured electrome-
chanically or with an optical technique (5). The 
electromechanical measurement principle is unaf-
fected by spectral interferences from haemolysis, 
but biological interference due to haemolysis is 
still tangible and cannot be overcome (6). The use 
of an optical technique and multiple wavelengths 
offers the possibility of a simultaneous check for 
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endogenous interfering substances such as hae-
moglobin, bilirubin or lipaemia – but the test itself 
is susceptible to those interferences (5). The bio-
logical interference from haemoglobin may be 
just as important as the analytical interference in 
coagulation testing because it affects both optical 
and mechanical instrumentation and is often over-
looked (1). We here present an example of interfer-
ence from lipaemia and haemolysis on an aPTT 
measurement, where the handling of this informa-
tion critically influenced the report of the test re-
sult in the post-analytical phase. 
Case report
A young boy was admitted with gastrointestinal 
bleeding. As part of the diagnostic workup differ-
ent coagulation parameters were measured and 
revealed normal international normalized ratio 
(INR) of 1.10 (reference range < 1.2) and normal fi-
brinogen activity of 1.87 g/L (ref. 1.77 – 4.29 g/L) 
but a prolonged aPTT > 300 seconds (ref. 22 - 28 
seconds). Due to a hereof relevant suspicion of 
haemophilia (and an expected high bleeding risk 
based on the aPTT result), coagulation factors (F) 
VIII and IX were measured and were normal: FVIII 
was 0.92 x 103 IU/L (ref. 0.60 - 1.50) and FIX 1.89 x 
103 IU/L (ref. 0.60 - 1.50). Coagulation parameters 
were all measured on Sysmex CS-5100 (Siemens 
Healthcare A/S, Ballerup, Denmark) using optical 
technology. 
To unravel this discrepancy, aPTT was measured 
on an alternative coagulation instrument, STA-R 
(Triolab AS, Broendby, Denmark), using an electro-
mechanical measurement principle, which re-
vealed a normal aPTT of 34 seconds (ref. 27 - 40 
seconds). 
Due to normal INR, normal fibrinogen, normal 
FVIII and FIX and a normal aPTT measured with 
electromechanical technique the troubleshooting 
was focused on the aPTT result > 300 seconds us-
ing the optical technique. Based on the normal 
aPTT result from the same specimen with another 
method, interference from heparin was excluded. 
Factors VIII, IX and aPTT measured with a mechani-
cal method were analysed on the same specimen 
as the previous analyses and not a redrawn sample. 
The Graph Detail Print from the patient sample re-
vealed a clotting curve as shown in Figure 1. The 
shape of the curve indicates that no clotting point 
is detectable. For comparison, a normal curve is 
shown in Figure 2. Due to the abnormal curve, the 
flag code “no coagulation” was added automatical-
ly from the analysis equipment and the result of 
the aPTT replaced by asterisks (*****). In such a sit-
uation, the local standard operating procedure 
(SOP) describes that the laboratory technician 
must check if the sample is coagulated, and only if 
the sample is not coagulated, an aPTT result > 300 
seconds can be released. In this case, the sample 
was not coagulated and the situation was actually 
Figure 1. The aPTT measurement curve in the patient sample. 
X-axis: time (s), Y-axis: aPTT-value (s). aPTT - activated partial 
thromboplastin time.
Figure 2. A normal aPTT measurement curve. aPTT - activated 
partial thromboplastin time.
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handled according to the SOP. Unfortunately, the 
local SOP did not describe action steps in case of 
the error “no coagulation” precisely enough. Ac-
cording to the manufacturer’s check algorithm, 
the sample must be checked for spurious etiology 
(i.e. pre-analytical errors or unknown anticoagu-
lant therapy) in case of a “no coagulation” mes-
sage. If HIL notifications appear and the result of 
aPTT is replaced by asterisks, the test result must 
however not be released, but instead replaced by 
the relevant interference code. In this case, the 
Graph Detail Print also revealed two other flag 
codes, namely “haemolysed sample” and “lipemic 
sample”. Consequently, the “no coagulation” code 
should have been overruled by the interference 
codes for haemolysis and lipaemia, which unfortu-
nately passed unnoticed. This was possible be-
cause the possibility of a flag code “no coagula-
tion” in the presence of increased HIL indices was 
not anticipated, and the combination of these was 
therefore not comprised by the SOP.  
What happened?
The aPTT result was corrected to 34 seconds in the 
medical report and the clinicians were informed 
on the laboratory error. Also, the clinicians were in-
formed on the highly lipaemic and haemolysed 
sample. Plasma triglycerides measurement was 
consequently performed revealing severely in-
creased triglycerides of 7.59 mmol/L (ref. < 2.00 
mmol/L).
Also, the local SOP was corrected: In case of other 
codes than “no coagulation” and a result replaced 
by asterisks, the aPTT result must never be re-
leased. 
Discussion
Inappropriate handling of test results, either by 
the laboratory or by the clinician doing the inter-
pretation, can have harmful consequences (7). Es-
pecially, errors related to coagulation testing can 
have clinically significant consequences if placing 
the patient at risk of bleeding or thrombosis (7). 
An aPTT > 300 seconds is associated with in-
creased bleeding risk unless the reason is pres-
ence of lupus anticoagulant (LA), which is known 
to cause false prolongation of aPTT (8). In our case, 
the aPTT prolongation erroneously indicated that 
the patient had an increased bleeding risk, which 
potentially could have influenced the clinical deci-
sion-making and postponed further investigations 
of the patient’s symptoms, if these had included 
operative procedures contraindicated in case of 
increased bleeding risk. 
Influence of haemolysis and lipaemia on coagula-
tion testing represents well-known diagnostic 
challenges. The complexity of haemostasis and 
also of the analytical methods makes the coagula-
tion analyses vulnerable to these interferences (1). 
For this reason, it is also explicitly stated in stand-
ard guideline H21-A5 from the Clinical and Labora-
tory Standards Institute (CLSI) that haemolysed, ic-
teric or lipaemic samples represent a serious chal-
lenge in plasma-based coagulation and molecular 
haemostasis assays (3). 
The degree of interference from HIL varies de-
pending on the aPTT method used (9). Evidence of 
influence from haemolysis on routine coagulation 
testing shows that aPTT can be prolonged in 
haemolysed patient samples but shortened in 
samples from healthy volunteers subjected to me-
chanical haemolysis when using a MDA-II analyser 
(10). Shortening of aPTT was also observed in 
spiked samples from healthy volunteers using 
Behring Coagulation System (Dade-Behring, Mar-
burg, Germany), whereas spiking patient samples 
with normal aPTT with haemolytic haemoglobin 
prolonged the aPTT value using Sysmex CS-2100i 
(9,11).
Regarding lipaemia, research groups have com-
pared routine coagulation testing on optical in-
struments with those of a mechanical clot detec-
tion-based analyser. Comparison of aPTT mea-
surements from Sysmex CA-6000 and STA-R in li-
paemic samples (triglycerides concentration rang-
ing between 2.42 and 18.70 mmol/L) found a high 
correlation between aPTT results from the two an-
alysers (r = 0.988) (12). In a large volume hospital 
laboratory, Sysmex CA-1500 compared to STA-R 
also showed a high correlation between aPTT in 
turbid samples (13). Thus, current evidence does 
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not indicate any significant impact of turbidity on 
photo-optical detection as well as mechanical de-
tection on aPTT measurements, whereas the liter-
ature regarding haemolysis and aPTT results is 
more inconsistent. 
When handling common interferences related to 
sample integrity such as HIL, clinical laboratories 
often rely on the documentation of HIL estimates 
and interference levels given by the manufacturer. 
However, it is important for the laboratories to 
evaluate this information for clinical practice and 
patient safety to prevent reporting of erroneous 
values. Also, the laboratories must consider a way 
to avoid rejecting too many samples, where the 
result perhaps could be valuable to the patient de-
spite an increased uncertainty due to e.g. haemol-
ysis (14). In general, laboratories cannot rely solely 
on guidelines or manufacturer information to as-
sure correct interpretation – they are obliged to 
confirm this as part of their mandatory assay verifi-
cation due to the ISO15189 standard. 
Modern instrumentation and improved test per-
formance decreases the risk of analytical errors in 
laboratory testing, but increasing lab automation 
is however a challenge when it comes to assur-
ance of sample integrity. Errors observed in re-
ported test results are therefore far more likely to 
be related to pre- or post-analytical issues, and fo-
cus on post-analytical handling of pre-analytical 
issues are therefore more relevant than ever, espe-
cially when implementing new equipment (which 
was the case here) – and in this regard involve-
ment of the manufacturers are mandatory (6). Fur-
thermore, the medical doctors in clinical biochem-
istry and specialists in laboratory medicine are piv-
otal in evaluating the influence of pre-analytical 
issues on the post-analytical phase as they consti-
tute an important academic link between the lab-
oratory and the clinicians. So an optimal handling 
of pre- as well as post-analytical issues and how to 
handle or avoid these warrants close cooperation 
between the manufacturer, the laboratory special-
ists, and the clinicians. 
What YOU should / can do in your 
laboratory to prevent such errors 
•	 Laboratories must check HIL indices before an-
ything else is done on the sample. 
•	 Laboratories must be aware of the possibility of 
more than one flag code in routine testing, 
here shown for coagulation tests on Sysmex 
CS-5100.
•	 If the HIL indices constitute one or more flag 
codes, the action of these should always over-
rule the action of any other flag codes if the re-
sult is replaced by asterisks when using Sysmex 
CS-5100.
•	 Flag codes should prompt further investigation 
of the cause, but the final interpretation and 
decision must be carried out by the laboratory 
specialist.
•	 In the increasingly automated laboratory, 
awareness on pre- and post-analytical issues, 
especially if they combine, must be strength-
ened.
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